Evaluation of the safety and effectiveness of nevirapine plus coformulated tenofovir/emtricitabine as first-line therapy in routine clinical practice

AIDS Research and Human Retroviruses

Volumn 28, Issue 2, 2012, Pages 165-170

  Vallecillo, Gabriel ^a,i   Domingo, Pere ^b,i   Mallolas, Josep ^c,j   Blanch, Jesús ^d   Ferrer, Elena ^e,j   Cervantes, Manuel ^f   Pedrol, Enric ^g   Knobel, Hernando ^a   Llibre, Josep M ^h,i  

^a HOSPITAL DEL MAR   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d Hospital Residencia Sant Camil   (Spain)

^e HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^f HOSPITAL DE SABADELL   (Spain)

^g Hospital Sant Pau i Santa Tecla   (Spain)

^h HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

ⁱ UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^j UNIVERSITY OF BARCELONA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEVIRAPINE; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG SCREENING; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EXFOLIATIVE DERMATITIS; FEMALE; GASTROINTESTINAL SYMPTOM; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERTRANSAMINASEMIA; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MYALGIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADENINE; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DEOXYCYTIDINE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; NEVIRAPINE; PHOSPHONIC ACIDS; RNA, VIRAL; SPAIN; VIRAL LOAD;

EID: 84858036044     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0092     Document Type: Article

References (30)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV- 1-infected adults and adolescents. Department of Health and Human Services. January 10, 2011; 1-166. Available at www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed February 24, 2011.
2. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, et al.: International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010;304(3):321-333.
3. European AIDS Clinical Society: Clinical Management and Treatment of HIV Infected Adults in Europe. Version 5-2. Available at http:// europeanaidsclinicalsociety.org/guidelines.asp. Accessed February 24, 2011.
4. Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update January 2011). Available at www.gesida.seimc.org/index.asp. Accessed February 24, 2011.
5. Molina JM, Andrade-Villanueva J, Echevarria J, et al.: CASTLE Study Team. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr 2010;53:323-332.
6. Daar ES, Tierney C, Fischl MA, et al., for the AIDS Clinical Trials Group Study A5202 Team: Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV type-1: A randomized trial. Ann Intern Med 2011;154(7):445-456.
7. Riddler SA, Haubrich R, DiRienzo AG, et al.: Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008;358:2095-2106. (Pubitemid 351679596)
8. Mills AM, Nelson M, Jayaweera D, et al.: Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 2009;23:1679-1688.
9. Lennox JL, De Jesus E, Lazzarin A, et al.: Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: A multicentre, double-blind randomized controlled trial. Lancet 2009;374:796-806.
10. van Leth F, Phanuphak P, Ruxrungtham K, et al.: Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: A randomised open-label trial, the 2NN Study. Lancet 2004;363:1253-1263. (Pubitemid 38496486)
11. Soriano V, Arastéh K, Migrone H, Lutz T, Opravil M, Andrade-Villanueva J, et al.: Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naïve HIV-1 patients: The ARTEN Trial. Antiv Ther 2011;16(3):339-348.
12. De Jesus E, Mills A, Bhatti L, et al.: Nevirapine (NVP) vs ritonavir-boosted atazanavir (ATV/r) combined with tenofovir/ emtricitabine (TDF/FTC) in first-line therapy: NEWART 48-week data. Tenth International Congress on Drug Therapy in HIV Infection. November 7-11, 2010, Glasgow. Abstract S4P4.
13. Lapadula G, Costarelli S, Quiros-Roldan E, et al.: Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients. Clin Infect Dis 2008;46:1127-1129. (Pubitemid 351589888)
14. Rey D, Hoen B, Chavanet P, et al.: High rate of early virological failure with the once-daily tenofovir/lamivudine/ nevirapine combination in naive HIV-1-infected patients. J Antimicrob Chemother 2009;63:380-388.
15. Chan-Tack KM, Struble KA, Morgensztejn N, et al.: HIV clinical trial design for antiretroviral development: Moving forward. AIDS 2008;22:2419-2427.
16. Division of AIDS Tables for grading the severity of adult and pediatric adverse events. Version 1.0, December 2004, Clarification August 2009. Available at www.niaid.nih.gov.
17. Nachega JB, Hislop M, Dowdy DW, et al.: Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med 2007;146:564-557.
18. Johnson M, Soriano V, Brockmeyer N, et al.: Early virological and immunological response is comparable for nevirapine and RTV-boosted atazanavir: An ARTEN sub-analysis. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2009). San Francisco, September 12-15, 2009. Abstract H-924c.
19. Eden A, Andersson LM, Andersson O, et al.: Differential effects of efavirenz, lopinavir/r, and atazanavir/r on the initial viral decay rate in treatment naïve HIV-1-infected patients. AIDS Res Hum Retroviruses 2010;26:533-540.
20. Wainberg MA: HIV resistance to nevirapine and other non-nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2003;34:S2-7. (Pubitemid 37158627)
21. Parienti JJ, Massari V, Descamps D, et al.: Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. Clin Infect Dis 2004;38:1311-1316. (Pubitemid 38608576)
22. de Béthune MP: Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: A review of the last 20 years (1989-2009). Antiviral Res 2010;85(1):75-90.
23. Novak RM, Chen L, MacArthur RD, et al.: Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: Implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis 2005;40:468-474. (Pubitemid 40216518)
24. Simen BB, Simons JF, Hullsiek KH, et al.: Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis 2009;199:693-701.
25. Rodríguez-Arrondo F, Aguirrebengoa K, Portu J, et al.: Long-term effectiveness and safety outcomes in HIV-1- infected patients after a median time of 6 years on nevirapine. Curr HIV Res 2009;7:526-532.
26. Bonjoch A, Paredes R, Domingo P, et al.: Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients. AIDS Res Hum Retroviruses 2006;22:321-329.
27. Clotet B, van der Valk M, Negredo E, et al.: Impact of nevirapine on lipid metabolism. J Acquir Immune Defic Syndr 2003;34:S79-84. (Pubitemid 37158637)
28. Kotler DP: HIV and antiretroviral therapy: Lipid abnormalities and associated cardiovascular risk in HIV-infected patients. J Acquir Immune Defic Syndr 2008;49:S79-85.
29. Grunfeld C: Dyslipidemia and its treatment in HIV infection. Top HIV Med 2010;18:112-118.
30. Podzamczer D, Andrade-Villanueva J, Clotet B, Taylor S, Rockstroh J, Reiss P, et al.: Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN Study). HIV Med 2011;12(6):374-382.